Press Release: Vaxcyte Announces Pricing of -2

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF(R), its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte's system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. Forward-Looking Statements This press release contains forward-looking statements regarding Vaxcyte, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the completion, timing and expected closing of the offerings, the expected amount of the gross proceeds of the offerings and the intended use of the net proceeds therefrom. Words such as "expects," "intends," "intended," "designed," "aim," "will" and "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements represent Vaxcyte's current expec